KOK-opplevelsen er en varm omfavnelse forbeholdt alle – en naturlig symbiose, varmt blandet med kaldt, inne og ute. Vi er her for å gi deg pusterom, hvile, varme og begeistrende opplevelser hele året. Hyttestemning og sansefest, knitrende peis og duftende vanndamp. Aufguss, avslappning og friske fjordopplevelser. Har du ikke prøvd? Samle en gjeng og kast deg ut i det du også, vi lover at du ikke vil angre.

EKKO MEDIA ER NORGES FØRSTE DIGITALE MEDIEBYRÅ SPESIALISERT MOT EIENDOMSMARKEDET.Ekko leverer digitale markedsføringsløsninger for eiendomsprosjekter og meglere i hele Norge. Vi har fokus på utvikling av ny teknologi for å alltid ligge langt foran konkurrentene. Byrået ble startet opp i 2013 av gründerne Lars Henrik Sand og Asgeir Brude Wærås. De opplevde at eiendomsbransjen var preget av byråer som var sterke på fagfelt som 3D eller nettsider, men de så et behov for spesialisering av digital markedsføring. På kort tid har byrået vokst til en meget sterk aktør innen digital markedsføring, hvor mye av grunnen til den sterke veksten er byråets nysgjerrighet, engasjement og serviceinnstilling. Med disse egenskapene er Ekko Media alltid med på å skape nye metoder, strategier og markedsanalyser – som igjen gir et unikt fortrinn i et marked som aldri står stille.

Dig Science increases certainty in oil & gas exploration by using Artificial Intelligence as a de-risk factor for geological interpretation. A new dawn is upon the oil & gas industry. Recent technology advances combined with increased computer capacity is disrupting conventional workflows in the industry. A new mindset is allowing geoscientists to join forces with data scientists, thereby enabling the industry to develop more integrated and powerful machine learning algorithms. These will contribute to a higher exploration success rate and improved oil recovery. Dig Science´s mission is to substantially de-risk oil & gas exploration in new and underexplored areas, as well as ensure advantages to already existing exploration portfolios.

The Lyfstone diagnostic tests are ready for distribution to pilot clients, and will have a full scale, international commercial launch Q3-2018 Artificial joints are one of the most important medical successes of our time Unfortunately this success has created a new problem – these implants loosen over time and have to be revised Currently, diagnosis of loosening is unclear and the revision surgeries are both complex and costly Lyfstone gives surgeons and patients a clear and objective diagnostic tool for determining the need to proceed with a revision procedure or not

GI ALLE MULIGHET TIL Å INVESTERE I VEKSTSELSKAPER GJENNOM AKSJEKJØP. Folkeinvest AS ønsker med webtjenesten folkeinvest.no å demokratisere investering i oppstartsselskaper.Emisjonsprosessen har frem til nå være komplisert både for selskapet og de som vil investere. Derfor har slike investeringer vanligvis kun blitt tilbudt bekjente av selskapet og profesjonelle investorer.Folkefinansiering med lave minstebeløp og en lettfattelig webtjeneste gir alle mulighet til å investere.Å investere i oppstartsselskaper er forbundet med risiko for at investeringen kan gå tapt. Mange selskaper overlever ikke sine fem første år. Men det er også i den fasen at verdistigningen kan bli høy. Vi mener at denne investeringsmuligheten bør være tilgjengelig for alle.Folkeinvest.no har åpne investorlister, diskusjonsforum og krav til dokumentasjon som gjør at aksjekjøpere er godt rustet til å ta investeringsbesluttninger.

eCommerce, B2B, and product development towards tactical, outdoor, and lifestyle products. Office and warehouse in Oslo and eCommerce presence 3 in Norway, Sweden, and Finland. 25 employees and 100MNOK revenue in 2018. We've been growing about 50% yearly over the last three years and aim to continue growing at the same speed. The young data-driven organization with ambitions to become the biggest player within our niche. Come and join us!

UpStacked is the All-in-One centralized operations platform that crushes SLA requirements to increase profitability and reduce OPEX. Purpose-built for internal IT and MSPs to operate SMBs and Enterprises. With user experience in mind, UpStacked drives complex to zero-touch, through automation and machine learning. UpStacked at a Glance: - All-in-One Centralized Platform - Enterprise onboarding in minutes - Third-Party integrations - Zero-Touch - Simplified License Management - Real-Time On-Demand Reporting - Real-Time Topology Based Correlation - Real-Time Event-Based Correlation - Built-in Role Based Access Control - Natively Multi-Tenant - Multi-Vendor - ITIL

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

BioPlan optimizes production planning for all steps in the aquaculture value chain, from roe to harvest.BioPlan's algorithms represent the state-of-the-art in production optimization. They are the result of many years of in-depth research and development, both in-house and at the Norwegian University of Science and Technology in Trondheim, Norway. BioPlan is today used for planning salmon production with an annual sales value of 4 billion NOKOfficial launched of software in August 2017. Now building a customer base

We start our project in 2017. We develop and offer to the market ecological & sustainable fertilizers made by mineral and organic nature. We cultivate a unique product and engage experience and innovation. By offering a quality product with added value to our customers, we help make a cost-effective solution for horticulture and agriculture.  We are happy to be engaged in the optimization of performance for allied businesses and private customers.

Five seasoned experts with over 175 years of experience in the oil & gas industry have developed a new patent pending disruptive revolutionary technology.   Water is separated in a horizontal well bore close to the reservoir and thereafter re-injected via a lateral well as pressure support to increase oil recovery. The Fluidsep DPP combines production and injection in one well with no spill to the surface, all excess water and sand is re-injected and never sees the surfaceThe technology enables  35% extra oil production and at the same time results in significantly reduced CO2/barrel of Oil. More than a 30% reduction compared with conventional production. An example of simulations shows extra income of > 1 Billion NOK per well. Fluidsep DPP has achieved TRL 2 - and requires 2 years of qualifications and pilot testing to be ready for the market, TRL 7. Strong interest in the market about our technology. Currently inviting investors and Seed capital funds to participate in the joint development of building a new international downhole service provider based in the Bergen region.

Building a "børs"  for the worlds non for profit organisation in Oslo. Oslo Philanthropic Exchange is a non-profit foundation. Our mission is to bring the best practice from the global capital markets to raise philanthropic funding more efficiently. Our goal is to contribute to higher impact of philanthropic capital. The OPX Solution addresses the inefficient funding of the non-profit sector and the lack of standardised, transparent and comparable data. By applying best practice from the capital markets for listing of non-profit organisations and reporting requirements as well as leveraging existing infrastructures, we standardise and digitalise to increase efficiency, transparency, accountability and accessibility. The OPX Solution represent the complete value chain of finding, filtering, funding and following the world’s non-profit organisations.

Momentum Technologies is a specialist company with a focus on preventing stress and fatigue in vital equipment and structures in the oil and gas industry. Fatigue in oil and gas leading pipes can lead to fire and explosions and may cause large-scale accidents. Through unique expert services and solutions within vibration and sound, Momentum Technologies provides fatigue prevention. Momentum Technologies’ core competency is in the understanding of the underlying physics of vibrations. We break down the problem, make it understandable, and provide targeted and cost-efficient solutions.

Exabel is an artificial intelligence startup based in Oslo, Norway. Exabel’s mission is to synthesize the world’s information and learn how it evolves. We are developing a smart digital assistant software tool for professional investment managers. We are currently a team of 6 full-time employees, with diverse backgrounds; two mathematicians, three software engineers, and a business developer. Combined, we have strong experience with companies like Google, Medallia, Arctic Securities, Intelligent Trading, Microsoft, and Brain Corporation. We are located in Forskningsparken, by StartupLab. The company is well funded for several years of research, product development, and market launch.